Jade Biosciences Files 8-K with Material Agreements and Disclosures
Ticker: JBIO · Form: 8-K · Filed: Oct 7, 2025 · CIK: 1798749
Sentiment: neutral
Topics: material-agreement, equity-sale, disclosure
TL;DR
Jade Biosciences (fka Aerovate) filed an 8-K on 10/3/25 covering material agreements, equity sales, and financial updates.
AI Summary
On October 3, 2025, Jade Biosciences, Inc. filed an 8-K report detailing several key events. The company entered into a Material Definitive Agreement, reported on Unregistered Sales of Equity Securities, made a Regulation FD Disclosure, and included Financial Statements and Exhibits. Jade Biosciences, Inc. was formerly known as Aerovate Therapeutics, Inc., with a name change effective January 3, 2020.
Why It Matters
This 8-K filing signals significant corporate activity and potential strategic shifts for Jade Biosciences, Inc., impacting investors' understanding of its current operational and financial standing.
Risk Assessment
Risk Level: medium — The filing involves material definitive agreements and unregistered sales of equity, which can indicate significant corporate actions and potential dilution or financing events.
Key Players & Entities
- Jade Biosciences, Inc. (company) — Registrant
- Aerovate Therapeutics, Inc. (company) — Former company name
- October 3, 2025 (date) — Date of earliest event reported
- January 3, 2020 (date) — Date of name change
- 221 Crescent St., Building 23, Suite 105, Waltham, MA 02453 (address) — Principal executive offices
FAQ
What type of Material Definitive Agreement did Jade Biosciences, Inc. enter into?
The filing does not specify the nature of the Material Definitive Agreement, only that one was entered into on or before October 3, 2025.
What were the details of the Unregistered Sales of Equity Securities?
The 8-K filing indicates that unregistered sales of equity securities occurred, but specific details such as the number of shares, price, or purchasers are not provided in this summary section.
What is the significance of the Regulation FD Disclosure?
The Regulation FD Disclosure indicates that the company is providing material information to the public in a non-discriminatory manner, as required by the SEC's fair disclosure rules.
When did Jade Biosciences, Inc. change its name from Aerovate Therapeutics, Inc.?
The name change from Aerovate Therapeutics, Inc. to Jade Biosciences, Inc. was effective on January 3, 2020.
Where are Jade Biosciences, Inc.'s principal executive offices located?
Jade Biosciences, Inc.'s principal executive offices are located at 221 Crescent St., Building 23, Suite 105, Waltham, MA 02453.
Filing Stats: 1,980 words · 8 min read · ~7 pages · Grade level 12.1 · Accepted 2025-10-07 07:13:40
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share JBIO The Nasdaq
- $135 m — gregate purchase price of approximately $135 million, (i) an aggregate of 13,368,164 s
- $9 — Common Stock"), at a price per share of $9.14, and (ii) pre-funded warrants (the "
- $9.1399 — of Common Stock at a purchase price of $9.1399 per Pre-Funded Warrant, which represent
- $22.0 million — mpany is obligated to pay Paragon up to $22.0 million based on specific development, regulato
- $1.5 million — t to reach such milestones, including a $1.5 million fee for nomination of a development can
- $2.5 million — 025, and a further milestone payment of $2.5 million upon the first dosing of a human patien
Filing Documents
- d58004d8k.htm (8-K) — 44KB
- d58004dex41.htm (EX-4.1) — 83KB
- d58004dex101.htm (EX-10.1) — 262KB
- d58004dex102.htm (EX-10.2) — 87KB
- d58004dex991.htm (EX-99.1) — 12KB
- d58004dex992.htm (EX-99.2) — 19KB
- d58004dex993.htm (EX-99.3) — 46KB
- g58004ex99_3p10g1.jpg (GRAPHIC) — 235KB
- g58004ex99_3p11g1.jpg (GRAPHIC) — 359KB
- g58004ex99_3p12g1.jpg (GRAPHIC) — 334KB
- g58004ex99_3p13g1.jpg (GRAPHIC) — 262KB
- g58004ex99_3p14g1.jpg (GRAPHIC) — 284KB
- g58004ex99_3p15g1.jpg (GRAPHIC) — 331KB
- g58004ex99_3p16g1.jpg (GRAPHIC) — 227KB
- g58004ex99_3p17g1.jpg (GRAPHIC) — 332KB
- g58004ex99_3p18g1.jpg (GRAPHIC) — 319KB
- g58004ex99_3p19g1.jpg (GRAPHIC) — 321KB
- g58004ex99_3p1g1.jpg (GRAPHIC) — 171KB
- g58004ex99_3p20g1.jpg (GRAPHIC) — 310KB
- g58004ex99_3p21g1.jpg (GRAPHIC) — 393KB
- g58004ex99_3p22g1.jpg (GRAPHIC) — 136KB
- g58004ex99_3p23g1.jpg (GRAPHIC) — 406KB
- g58004ex99_3p24g1.jpg (GRAPHIC) — 263KB
- g58004ex99_3p25g1.jpg (GRAPHIC) — 226KB
- g58004ex99_3p26g1.jpg (GRAPHIC) — 278KB
- g58004ex99_3p27g1.jpg (GRAPHIC) — 325KB
- g58004ex99_3p28g1.jpg (GRAPHIC) — 294KB
- g58004ex99_3p29g1.jpg (GRAPHIC) — 246KB
- g58004ex99_3p2g1.jpg (GRAPHIC) — 641KB
- g58004ex99_3p30g1.jpg (GRAPHIC) — 349KB
- g58004ex99_3p31g1.jpg (GRAPHIC) — 130KB
- g58004ex99_3p32g1.jpg (GRAPHIC) — 221KB
- g58004ex99_3p33g1.jpg (GRAPHIC) — 269KB
- g58004ex99_3p34g1.jpg (GRAPHIC) — 122KB
- g58004ex99_3p35g1.jpg (GRAPHIC) — 164KB
- g58004ex99_3p3g1.jpg (GRAPHIC) — 280KB
- g58004ex99_3p4g1.jpg (GRAPHIC) — 148KB
- g58004ex99_3p5g1.jpg (GRAPHIC) — 279KB
- g58004ex99_3p6g1.jpg (GRAPHIC) — 340KB
- g58004ex99_3p7g1.jpg (GRAPHIC) — 335KB
- g58004ex99_3p8g1.jpg (GRAPHIC) — 285KB
- g58004ex99_3p9g1.jpg (GRAPHIC) — 342KB
- 0001193125-25-232562.txt ( ) — 14530KB
- jbio-20251003.xsd (EX-101.SCH) — 3KB
- jbio-20251003_lab.xml (EX-101.LAB) — 19KB
- jbio-20251003_pre.xml (EX-101.PRE) — 12KB
- d58004d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Jade Biosciences, Inc. Date: October 7, 2025 By: /s/ Tom Frohlich Name: Tom Frohlich Title: Chief Executive Officer